By Sahar Chmais
Kids 5 to 11 years old may soon be eligible for Pfizer’s COVID-19 vaccine after trials showed 'favorable safety' and a 'robust antibody response', according to Pfizer.
The trial for this age group had 2,268 participants who received a lower two-dose regimen than those ages 12 and older. The vaccine was well tolerated, with side effects comparable to participants 16 to 25 years of age, according to Pfizer. Although these elementary-aged kids received 10 micrograms in each vaccine, they developed the same antibody levels that were found in teenagers and young adults who received 30 micrograms.
PLEASE LOG IN FOR PREMIUM CONTENT. Our website requires visitors to log in to view the best local news.
Not yet a subscriber? Subscribe today!










